公开(公告)号：EP4219470A1

公开(公告)日：2023-08-02

申请号：EP22209765.1

申请日：2018-01-16

申请人： Astrazeneca AB

发明人： NILSSON, Karl Magnus ,  ÅSTRAND, Annika Birgitta Margareta ,  BERGGREN, Anna Ingrid Kristina ,  JOHANSSON, Johan R ,  LEPISTÖ, Matti Juhani ,  KAWATKAR, Sameer Pralhad ,  SU, Qibin ,  KETTLE, Jason Grant

IPC分类号： C07D403/04 ,  C07D403/14 ,  A61K31/506 ,  A61P17/14 ,  A61P37/00

摘要： Disclosed herein are compounds of Formula (I),

and pharmaceutically acceptable salts thereof, wherein Ri-Rs have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

公开(公告)号：EP1252142A1

公开(公告)日：2002-10-30

申请号：EP01900494.4

申请日：2001-01-11

申请人： AstraZeneca AB

发明人： FAULL, Alan Wellington ,  KETTLE, Jason Grant

IPC分类号： C07D209/42 ,  A61K31/404 ,  A61P29/00

CPC分类号： C07D209/42

摘要： A compound of formula (I) wherein: R1 is hydrogen, halo or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is a halo group or a trifluoromethyl group; R4 is a halo group or a trifluoromethyl group; R5 is hydrogen or halo; R6 is hydrogen or halo; provided that when R?5 and R6¿ are both hydrogen, and one of R3 or R4 is chloro or fluoro, then the other is not chloro or fluoro; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonising an MCP-1 mediated effect in a warm-blooded animal such as a human being.

公开(公告)号：EP1670786A1

公开(公告)日：2006-06-21

申请号：EP04768629.0

申请日：2004-09-22

申请人： AstraZeneca AB

发明人： BRADBURY, Robert Hugh ,  HALSALL, Christopher Thomas ,  HENNEQUIN, Laurent Francois Andre ,  KETTLE, Jason Grant ,  PLOWRIGHT, Alleyn

IPC分类号： C07D403/12 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  A61K31/517 ,  A61P35/00

CPC分类号： C07D403/12 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14

摘要： The invention concerns a quinazoline derivative of the Formula (I): wherein each of the variables have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.

摘要翻译： 本发明涉及式（I）的喹唑啉衍生物：其中每个变量具有说明书中定义的任何含义; 它们的制备方法，含有它们的药物组合物以及它们在制备用作抗增殖剂的药物中的用途，所述药物用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤。

公开(公告)号：EP4373817A1

公开(公告)日：2024-05-29

申请号：EP22754791.6

申请日：2022-07-19

申请人： Astrazeneca AB

发明人： NILSSON LILL, Sten ,  GIBLIN, Kathryn ,  KETTLE, Jason Grant ,  GOLDBERG, Frederick Woolf ,  GRIMSTER, Neil Patrick ,  MORRILL, Lucas ,  ESCOBAR, Randolph ,  METRANO, Anthony ,  SONG, Kun ,  SHEPPECK, James ,  ZIEGLER, Robert Evans ,  WU, Ye ,  SHA, Li ,  WU, Dedong ,  GREBE, Tyler ,  MFUH, Adelphe ,  BALAZS, Amber ,  SHIELDS, Jason

IPC分类号： C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D519/00 ,  A61P35/00 ,  A61K31/497

CPC分类号： C07D403/14 ,  C07D405/14 ,  C07D417/04 ,  C07D403/04 ,  C07D409/14 ,  C07D413/14 ,  C07D519/00 ,  C07D401/14 ,  A61P35/00

公开(公告)号：EP3727355A1

公开(公告)日：2020-10-28

申请号：EP18842738.9

申请日：2018-12-20

申请人： AstraZeneca AB

发明人： YANG, Bin ,  KETTLE, Jason Grant ,  HAYHOW, Thomas George Christopher ,  RASMUSSON, Timothy Gordon ,  NISSINK, Johannes Wilhelmus Maria ,  FALLAN, Charlene ,  LAMONT, Gillian McGregor

IPC分类号： A61K31/00 ,  C07K5/00